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1607-551X/Copyright ª 2016, Kaohsiu
BY-NC-ND license (http://creativecomAbstract Acute pulmonary embolism (PE) carries a high risk of morbidity and mortality.
Delays in diagnosis or therapy may result in sudden, fatal deterioration; therefore, rapid diag-
nosis and an appropriate therapeutic approach are needed. We aimed to investigate the effect
of delaying thrombolytic administration on the mortality rate in a suspected PE. We retrospec-
tively analyzed 49 consecutive patients who were aged 18 years or older and received throm-
bolysis for a high-risk PE without a major contraindication. All patients were classified
according to the time of onset of the thrombolytic therapy. Patients experiencing cardiopul-
monary arrest were analyzed from the time of admission to thrombolytic administration with
10-minute cutoff values. Data were analyzed by a regression analysis and a receiver operating
characteristic (ROC) analysis for significant and independent associated risk factors and in-
hospital mortality. Mortality was seen in 17 of the 49 cases. Thirteen of these had received
thrombolytic therapy 1 hour after their emergency department (ED) admission. Among all
cases, the mortality rate was 35%. The ROC analysis indicated that a > 97-second delayed
thrombolytic administration time was associated with mortality with 53% sensitivity and 91%
specificity (area under the curve, 0.803; 95% confidence interval, 0.668e0.938). In the logistic
regression, a 5-minute delay in thrombolytic therapy (beta Z 1.342; 95% confidence interval,
1.818e2.231; pZ 0.001) was associated with in-hospital mortality in the multivariable model.
No major bleeding complications were seen in PE survivors. We conclude that early onseteclare no conflicts of interests.
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Thrombolytic therapy in acute pulmonary embolism 573thrombolytic therapy in the ED for high-risk and hemodynamically worsening patients appears
safe and life-saving.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Acute pulmonary embolism (PE) is the third leading cause of
cardiovascular morbidity and mortality. The mortality rate
of acute pulmonary embolism is about 30% in non-treated
patients and about 8% in treated patients. Approximately
11% of patients die of sudden death. Consequently, PE re-
mains a clinical challenge for physicians [1e3]. A PE results
from clots that form in the deep veins, dislodge and travel
through the venous system, and traverse the right ventricle
(RV) into the pulmonary vasculature. Then, owing to the
deterioration of the arterial circulation, pulmonary paren-
chymal necrosis may be seen [4,5].
A PE is classified as either nonmassive (low-risk patients),
submassive (intermediate-risk patients), or massive (high-
risk patients). These classifications are based on the mor-
tality risk indicated byhemodynamic parameters, right heart
function, and the presence of myocardial injury. Because of
high pulmonary arterial resistance, severe RV workload can
result in cardiogenic shock and cardiac arrest [1,3,6].
For in-patients for whom there is a high clinical suspicion
of PE and unstable hemodynamics, transferring to computed
tomography angiography (CTA) is unsafe. When CTA is not
available or is unsafe, bedside transthoracic echocardiog-
raphymight be helpful for a presumptive diagnosis. Based on
the echocardiographic findings, thrombolytic therapy can be
initiated [7]. A short time to diagnosis and initiation of
thrombolytic therapy are crucial and vital. Therefore, when
patients are admitted to the emergency department (ED)
with hemodynamic deterioration and a high clinical suspi-
cion of a PE, emergency physicians should immediately
implement thrombolytic therapy when no contraindications
coexist [1,8,9]. A recent study showed that extracorporeal
membrane oxygenation and ultrasound-accelerated cath-
eter-directed thrombolysis can be highly effective for man-
aging selected patients with a PE and cardiac arrest [10].
Although the indications, dosing regimens, bleeding
risks, and efficacies of different classes of thrombolytics
have all been studied, the timing of administration is
relatively understudied. Therefore, no consensus exists as
to when to administer these agents to obtain the maximum
benefit taking into account the door-to-needle time.
Therefore, we aimed to retrospectively investigate the
effect of the timing of thrombolytic administration on
mortality rate in patients with a suspected PE.
Methods
Study design and setting
This is a retrospective observational study conducted in the
ED at the Antalya Training and Research Hospital, Antalya,
Turkey between December 2012 and December 2015.Patient population and data collection
Patients aged 18 years or older who received thrombolytic
therapy for a suspected PE were eligible for the study. We
obtained data on demographic characteristics (age and sex)
and vital signs [blood pressure (BP) and heart rate (HR)].
Furthermore, data regarding arterial oxygen saturation
(SaO2), respiratory rate (RR), body temperature, laboratory
results, electrocardiography (ECG), imaging studies, PE
severity index (PESI), time of ED presentation and reper-
fusion therapy, time of cardiopulmonary arrest and post-
arrest reperfusion treatment administration time, 24-hour
mortality, and morbidity were extracted.
Bedside focused cardiac ultrasonography or echocardi-
ography was performed by the emergency physician or
cardiologists to detect an enlarged RV, the D-shaped sign,
hypokinetic lateral wall, and hyperkinetic apex of the RV
(McConnell’s sign), or for visualization of the clot. The
echocardiographic signs of RV dysfunction were accepted as
the indication for administering thrombolytic therapy in
patients with an overall hemodynamic status or clinical
condition that was too severe to allow CTA or when car-
diopulmonary arrest developed due to a presumed PE. In
patients who were hemodynamically stabilized or respon-
ded to cardiopulmonary resuscitation (CPR) after throm-
bolytic therapy, a PE was confirmed by CTA afterward.
Treatment plan
For thrombolytic therapy, the patients received tissue
plasminogen activator (rt-PA; Actilyse, Boehringer Ingel-
heim, Ingelheim, Germany) as a 10-mg bolus followed by a
90-mg bolus per continuous infusion of  2 hours via a
central line. HR, systolic and diastolic BP, mean arterial
pressure, and SaO2 by pulse oximetry were monitored and
recorded during the treatment.
Outcome measures
This study used 24-hour mortality rate in relation to the
time to thrombolytic administration as the primary
outcome measure. The secondary outcome measures were
major hemorrhages and fatal or intracranial bleeding in PE
survivors.
Statistical analysis
SPSS software version 21.0 for Windows (IBM Corp.,
Armonk, NY, USA) was used for the analysis of the study
data. The categorical variables were expressed as the fre-
quency and percentage, which were analyzed using the c2
and Fisher’s exact tests. The normal distribution of
continuous variables was tested using the ShapiroeWilk
Figure 1. Echo signs distribution in all patients.
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the mean  standard deviation and compared using the
Student t test. Non-normally distributed continuous
variables were analyzed using the ManneWhitney U test. A
two-tailed p value < 0.05 was considered statistically sig-
nificant. A receiver operating characteristic (ROC) curve
was plotted to analyze the time from admission to receipt
of thrombolytic therapy and its relation to in-hospital
mortality. A logistic regression was performed with a
multivariable model for independent association of
thrombolytic receiving time (door-to-needle) and other
clinical risk factors.Results
Our study was designed as retrospective and non-
randomized. In total, 49 patients with a PE were included
the following demographics: 27 (55%) women and 22 (45%)
men ranging in age from 35 years to 90 years (mean,
66.3  16.4 years). Admission symptoms included dyspnea,
77.5% (n Z 38); chest pain, 18.3% (n Z 9); fainting orFigure 2. D shape insyncope, 8.2% (n Z 4); dyspnea and syncope, 12.2%
(n Z 6); and dyspnea and chest pain, 12.2% (n Z 6). Risk
factors for a PE included immobilization, 42.8% (n Z 21);
active deep venous thrombosis, 14.3% (n Z 7); history of a
surgical procedure, 8.1% (n Z 4); and malignancy, 4.0%
(n Z 2).
Patient’s mean arterial pressure was 72.8  22.3 mmHg
at the time of ED admission. ECG findings included sinus
tachycardia in 75% (n Z 37) of the individuals, S1Q3T3
pattern in 66% (n Z 25), and right bundle branch block in
40% (n Z 20). CTA was obtained in 51% (n Z 25) of the
individuals and showed a thrombus in both pulmonary ar-
teries in all patients. Bedside focused cardiac ultrasonog-
raphy findings revealed an enlarged RV in 100% (n Z 49) of
the individuals, McConnell’s sign in 37% (nZ 18), D-shaped
sign in 30% (n Z 15), and mobile right thrombi in 12%
(n Z 6; Figure 1).
One of these cases, a 36-year-old man, presented to the
ED with sudden-onset dyspnea. His medical history was
notable for an orchiectomy performed 2 weeks earlier for a
testis tumor. His vital signs on admission were as follows:
BP, 70/40 mmHg; HR, 117 beats/min; SaO2, 70%; and RR,
32 breaths/min. An ECG showed right bundle branch block
and an S1Q3T3 pattern. The patient was unresponsive to
fluid resuscitation and inotropic support, and his PESI was
calculated as 136. Bedside cardiac ultrasonography
revealed severe dilation of the right heart chambers and
the D-shaped sign (Figure 2). The patient was considered to
have a PE with an extremely high risk of mortality and also
an absolute contraindication for thrombolytic therapy due
to the orchiectomy he underwent 2 weeks previously. He
developed cardiopulmonary arrest 10 minutes after
admission, and a return of spontaneous circulation (ROSC)
was observed 5 minutes after the initiation of CPR. Repeat
bedside ultrasonography showed persistence of the severe
right chamber dilation; the patient continued to be hypo-
tensive and he redeveloped cardiopulmonary arrest. For
these reasons, thrombolytic therapy was initiated 30 mi-
nutes after his ED admission and 20 minutes after the initialechocardiography.
Figure 3. Pulmonary artery occlusion by a large thrombus in
a pulmonary angiography patient.
Thrombolytic therapy in acute pulmonary embolism 575CPR. Although two short-lived ROSC periods occurred dur-
ing continuous CPR after the thrombolytic therapy, he once
again sustained a cardiac arrest and died despite 50 mi-
nutes of CPR.
Another patient, a 53-year-old woman with a fatal
course, was admitted to the ED with a 2-hour history of
dyspnea and chest pain. Her medical history was notable
for hypertension and diabetes mellitus. Her vital signs on
admission were as follows: BP, 80/50 mmHg; HR, 120 beats/
min; SaO2, 45%; and RR, 35 breaths/min. Her ECG showed a
supraventricular tachycardia with aberrant conduction.
The patient did not respond to fluid resuscitation and
inotropic support. Bedside cardiac ultrasonography
revealed severe dilation of the right heart chambers and
McConnell’s sign. Having a PESI score of 203, the patient
was deemed to have a very high risk for a PE, and a car-
diology consultation was obtained. She sustained a cardio-
pulmonary arrest 35 minutes after her ED admission, and an
ROSC was detected 10 minutes after the initiation of CPR.
The patient was taken to the catheterization laboratory
with the intent to perform coronary angiography with a
presumed diagnosis of acute coronary syndrome (ACS).
However, the coronary angiography revealed no coronaryTable 1 Comparison of clinical and demographic features of su
Characteristics Deceased (n Z
Age, y 70  16.1
Female sex 10 (58)
Time to thrombolytic administration < 1 h 4 (23)
Pulmonary artery pressure 62.3  8.4
Troponin 0.45  0.3
D-Dimer 4052  3224
Right bundle branch block 6 (35)
S1Q3T3 pattern on electrocardiogram 8 (47)
Blood pressure 62  27.1
Heart rate 93.70  41.8
Oxygen saturation 68.81  20.0
Temperature (C) 36.50  0.92
Data are presented as n (%) or mean  standard deviation.pathology. A subsequent pulmonary angiogram for a sus-
pected diagnosis of a PE showed a massive bilateral pul-
monary thromboembolism (Figure 3). The patient was thus
initiated on thrombolytic therapy with central line. How-
ever, she developed cardiopulmonary arrest in the cathe-
terization laboratory and died after being unresponsive to
all CPR efforts.
The rate of recovery without sequelae was significantly
improved in patients who received thrombolytic therapy
within the 1st hour after admission compared with the pa-
tients who died (pZ 0.007; Table 1). CPR was implemented
in seven surviving and 12 deceased patients. Two patients
had minor nosebleeds. None of the patients developed
major bleeding complications associated with thrombolytic
therapy, and all surviving patients recovered without
sequelae. In the ROC analysis, a thrombolytic delay of over
97 seconds predicted mortality with 53% sensitivity and 91%
specificity (area under the curve, 0.803; 95% confidence
interval, 0.668e0.938), upper bound (Figure 4).
The most delayed administration of thrombolytic ther-
apy was 185 minutes, right after coming to the hospital.
Because of the small number of mortal cases, the logistic
regression analysis was performed with a 5-minute delay to
increase the sensitivity of the thrombolytic administration.
In the logistic regression, a 5-minute thrombolytic delay
was associated with mortality in the multivariate model
[the model included systolic BP, age, echocardiographic RV
load, RV overload sign in ECG CPRþ or CPR, troponinþ or
troponin, deep vein thrombosis, systolic pulmonary artery
pressure, and PO2 (R
2 Z 0.751; Table 2)].Discussion
A high-risk PE is a medical emergency with life-threatening
consequences. Evidence from randomized and retrospec-
tive observational studies indicates that thrombolytic
therapy leads to early hemodynamic improvement. This
benefit comes at the cost of increased major bleeding. The
effect of thrombolytic therapy on mortality and the fre-
quency of recurrent thromboembolism remain question-
able. It is important to correctly diagnose a PE and to
initiate reperfusion therapy as early as possible [1,7,11,12].rviving and mortal cases.
17) Recovered without sequelae (n Z 32) p
63.14  16.8 0.486
17 (53) 0.769
24 (75) 0.001
57.43  9 0.389
0.68  0.9 0.458
4908  7187 0.355
14 (43) >0.99
17 (53) 0.071
80.66  10.26 0.001
2 109.90  12.04 0.046
2 80.74  12.42 0.020
36.62  1.21 0.726
Figure 4. Receiver operating characteristic (ROC) curve of
mortality for time to thrombolytic starting.
576 _I. Beydilli et al.A high-risk PE presumably leads to death by inducing RV
failure and associated profound hypotension. Urgent
administration of thrombolytic therapy based on the pres-
ence of RV dysfunction detected by bedside echocardiog-
raphy or focused cardiac ultrasonography eliminates a
blockage in the pulmonary vessels. This therapy also lowers
pulmonary resistance and pressure and restores more rapid
and complete normalization of right RV function and overall
hemodynamics. Although these tests have a low negative
predictive value that cannot reliably rule out a PE, the
literature data suggesting an extremely high risk of mor-
tality from a high-risk PE within the first few hours after an
ED admission were supported by our findings indicating a
24-hour survival rate of 94.1% achieved in patients who
received a thrombolytic therapy within 1 hour of admission.
We therefore suggest that early thrombolytic use isTable 2 Regression analysis of risk factors and mortality associ







Partial pressure of oxygen
Deep vein thrombosis
Right ventricular overload sign in electrocardiography
Troponin > cutoff value
Right ventricular load in echo
CI Z confidence interval.associated with a significantly lower likelihood of death
[1,13e16].
The prognosis of PE-induced hemodynamic shock (i.e., a
systolic BP < 90 mmHg or a decrease in the systolic BP
by  40 mmHg from baseline) is so poor that patients may
not survive the acute event, unless diagnosed and treated
early. Unfortunately, 25% of patients present with sudden
death without having a chance of being recognized or
receiving appropriate treatment; therefore, the possibility
of a rapid and fatal deterioration makes rapid diagnosis and
intervention crucial in this disorder [12,17e19]. All of the
patients in our study presented with profound hypotension
or shock and received thrombolytic therapy.
Mobile right heart thrombi are seen in approximately 4%
of patients with a PE, either on echocardiography or
computed tomography, and the proportion is higher, up to
18%, among patients who are critically ill [20,21]. Several
studies have shown the presence of a right heart thrombus
to be associated with RV dysfunction and high early mor-
tality [20e23]. As an example, data from an international
registry of patients with PEs reported that, compared with
patients without an RV thrombus, patients with an RV
thrombus had a higher 14-day and 3-month mortality (21%
vs. 11% and 29% vs. 16%, respectively) [20]. In our study,
four of our patients had RV thrombi.
Previous studies in the literature and recently published
guidelines recommend that thrombolytic therapy should be
instituted in patients with a presumably high-risk PE,
especially when no contraindications exist and other
possible diagnoses are excluded. In addition, catheter
directed thrombolysis (CDT) is recommended as a thera-
peutic maneuver in unstable patients when a PE is diag-
nosed by pulmonary angiography after ACS is excluded in
the catheterization laboratory. ACS is not a contraindica-
tion for thrombolytic therapy [1,24], and our patients
received thrombolytic therapy shortly after excluding ACS.
From this point of view, thrombolytic therapy can be
administered if the possibility of a PE is a higher risk than
ACS; however, if the possibility of ACS is a higher risk than a
PE, a primary percutaneous coronary intervention still
should be arranged first to rule out the possibility of ACS.
In our study, a thrombolytic delay of over 97 seconds
predicted mortality with 53% sensitivity and 91% specificity
(Figure 4).ation.
Beta 95% CI p
0.071 0.045 0.096 0.001
0.018 0.005 0.030 0.010
0.154 Not significant 0.302
0.126 Not significant 0.394
0.146 Not significant 0.291
0.193 Not significant 0.127
0.113 Not significant 0.436
0.026 Not significant 0.866
0.137 Not significant 0.306
0.101 Not significant 0.540
0.036 Not significant 0.723
Thrombolytic therapy in acute pulmonary embolism 577Although CPR was formerly considered a contraindica-
tion for institution of thrombolytic therapy because of the
possibility of hemorrhagic complications, recent data have
shown some success from systemic thrombolytic therapy
during CPR, especially when the cardiac arrest is due to a
suspected or confirmed acute PE [25,26]. Hence, the latest
advanced cardiovascular life support guidelines strongly
emphasize the use of thrombolytic therapy for a suspected
PE during CPR [9,18,24,27e31]. Survival is strongly affected
by the timing of thrombolytic administration, as demon-
strated by our logistic regression analysis, which found that
a 5-minute delay in thrombolytic treatment was signifi-
cantly associated with the 24-hour mortality. A 100% sur-
vival rate in patients who received thrombolytic therapy
within 10 minutes after cardiopulmonary arrest with no
bleeding complications in our study suggests that rescue
thrombolytic therapy should be initiated simultaneously
with resuscitation efforts for a successful resuscitation in
patients with a high-risk PE.
The most frightening complication of thrombolytic
therapy for a PE is bleeding, particularly an intracranial
hemorrhage. However, previous studies have provided
discordant bleeding rates, so a thorough evaluation of the
bleeding risk should be performed before the administra-
tion of a thrombolytic agent. Patients who are deemed to
be at high risk should ideally be treated by surgical embo-
lectomy or percutaneous catheter-directed treatment, if
adequate logistic and surgical or interventional expertise
exists for any given institution. As mentioned in the
guidelines, the absolute contraindications for thrombolytic
therapy become relative ones when a patient has an
extremely critical condition, such as an impending cardiac
arrest, and there is no time for interventional techniques.
The decision regarding thrombolysis should be individual-
ized by weighing the risks and benefits based on the pa-
tient’s age, comorbidities, hemodynamic status, and timely
manner [1,8,11,12,31e34]. In our first case presentation,
because the patient had a history of a surgery for a
testicular tumor, thrombolytic therapy was not initially
given due to this contraindication but was eventually
initiated 30 minutes after his ED admission and 20 minutes
after the initial CPR. We think that the patient may have
died due to this delay in the thrombolytic therapy.
The absence of any hemorrhagic complication in our
patients along with an overall survival rate of 63% and a
sequelae-free recovery in all patients leads us to believe
that thrombolytic therapy can be more liberally utilized in
cases of an impending arrest.Conclusion
The time to fibrinolytic therapy (door-to-needle time) has
been clearly determined in ACS and acute stroke although
the determination of a similar time frame in a PE, another
thromboembolic state, is not possible due to the lability of
a PE’s clinical course and the presence of other life-
threatening disorders in the differential diagnosis of a PE.
However, rescue thrombolysis for high-risk, hemodynami-
cally worsening patients appears life-saving when admin-
istered in the ED within 1 hour after admission or
10 minutes after cardiopulmonary arrest, although thebleeding risks are non-negligible. Future large-scale studies
are needed to confirm our results and to more clearly
define door-to-needle time for the administration of
thrombolytic therapy in a high-risk PE.
Current knowledge
High-risk PE presumably leads to death by inducing RV
failure and associated profound hypotension, so urgent
administration of thrombolytic therapy based on the pres-
ence of RV dysfunction detected by bedside echocardiog-
raphy or focused cardiac ultrasonography is recommended,
but no consensus exists regarding when to administer these
agents to obtain maximum benefit and how to consider a
door-to-needle time.
What this paper contributes to our knowledge
Thrombolytic therapy for high-risk PE appeared to be life-
saving on hemodynamically worsening patients when
administered within 1 hour of admission to ED or within
10 minutes of cardiopulmonary arrest, although bleeding
risks are non-negligible.
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